Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden, The Netherlands.
Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium.
Eur J Clin Pharmacol. 2019 Oct;75(10):1393-1404. doi: 10.1007/s00228-019-02708-y. Epub 2019 Jul 16.
There is a need for alternative analgosedatives such as dexmedetomidine in neonates. Given the ethical and practical difficulties, protocol design for clinical trials in neonates should be carefully considered before implementation. Our objective was to identify a protocol design suitable for subsequent evaluation of the dosing requirements for dexmedetomidine in mechanically ventilated neonates.
A published paediatric pharmacokinetic model was used to derive the dosing regimen for dexmedetomidine in a first-in-neonate study. Optimality criteria were applied to optimise the blood sampling schedule. The impact of sampling schedule optimisation on model parameter estimation was assessed by simulation and re-estimation procedures for different simulation scenarios. The optimised schedule was then implemented in a neonatal pilot study.
Parameter estimates were more precise and similarly accurate in the optimised scenarios, as compared to empirical sampling (normalised root mean square error: 1673.1% vs. 13,229.4% and relative error: 46.4% vs. 9.1%). Most importantly, protocol deviations from the optimal design still allowed reasonable parameter estimation. Data analysis from the pilot group (n = 6) confirmed the adequacy of the optimised trial protocol. Dexmedetomidine pharmacokinetics in term neonates was scaled using allometry and maturation, but results showed a 20% higher clearance in this population compared to initial estimates obtained by extrapolation from a slightly older paediatric population. Clearance for a typical neonate, with a post-menstrual age (PMA) of 40 weeks and weight 3.4 kg, was 2.92 L/h. Extension of the study with 11 additional subjects showed a further increased clearance in pre-term subjects with lower PMA.
The use of optimal design in conjunction with simulation scenarios improved the accuracy and precision of the estimates of the parameters of interest, taking into account protocol deviations, which are often unavoidable in this event-prone population.
新生儿需要替代的镇静药物,如右美托咪定。由于伦理和实际困难,在实施之前,应仔细考虑新生儿临床试验的方案设计。我们的目的是确定一种适合随后评估机械通气新生儿右美托咪定剂量需求的方案设计。
使用已发表的儿科药代动力学模型来推导首项新生儿研究中右美托咪定的给药方案。优化了采血方案的优化标准。通过不同模拟场景的模拟和重新估算程序来评估采样方案优化对模型参数估算的影响。然后在新生儿试验中实施了优化后的方案。
与经验采样相比(归一化均方根误差:1673.1%比13229.4%和相对误差:46.4%比9.1%),在优化方案中参数估计更加准确。最重要的是,偏离最佳设计的方案仍可进行合理的参数估计。来自试验组(n=6)的数据分析证实了优化试验方案的充分性。通过体表面积和成熟度对足月新生儿的右美托咪定药代动力学进行了标化,但结果显示该人群的清除率比通过从略大的儿科人群外推获得的初始估计值高 20%。典型新生儿(胎龄 40 周,体重 3.4kg)的清除率为 2.92 L/h。将研究扩展到 11 名额外的受试者后,发现胎龄较小的早产儿清除率进一步增加。
在考虑方案偏差的情况下,使用最佳设计结合模拟方案可提高参数估计的准确性和精密度,而方案偏差在这种事件高发人群中往往是不可避免的。